SEGMENT AND SIGNIFICANT CUSTOMER INFORMATION

12 Months Ended

Dec. 31, 2013

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

14. SEGMENT AND SIGNIFICANT CUSTOMER INFORMATION

We principally operate in the business segment described in Note 1. Pursuant to Codification Topic 280, Segment Reporting, we operate in one reportable business segment, that being the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries. Almost all of our internally funded product development expenses are in support of such products. The significant accounting policies of this segment are described in Note 2.

Our primary customers for the majority of our product sales (83%, 80% and 81% for the years ended December 31, 2013, 2012 and 2011, respectively) are in the U.S. dairy and beef industries. Product sales to international customers, who are also in the dairy and beef industries, aggregated 14%, 16% and 17% of our total product sales for the years ended December 31, 2013, 2012 and 2011, respectively. Sales to significant customers that amounted to 10% or more of total product sales are detailed in the following table:

	Year Ended December 31,
	2013			2012			2011
Animal Health International, Inc.(1)		38	%		35	%		38	%
MWI Veterinary Supply Company(2)		22	%		20	%		20	%

(1) Assumes that the June 2011 acquisition of Animal Health International by Lextron had occurred as of the beginning of the periods being reported.

(2) Assumes that the November 2013 acquisition of IVESCO, the October 2011 acquisition of Micro Beef Technologies and the March 2011 acquisition of Nelson Laboratories by MWI had each occurred as of the beginning of the periods being reported.

Accounts receivable due from significant customers amounted to the percentages of total trade accounts receivable as detailed in the following table:

	As of December 31,
	2013			2012
Animal Health International, Inc.		39	%		28	%
MWI Veterinary Supply Company(1)		26	%		19	%
Robert J. Matthews Company		10	%		*
TCS BioSciences, Ltd.		*			15	%

*Amount is less than 10%.

(1) Assumes that the November 2013 acquisition of IVESCO by MWI had occurred as of the beginning of the periods being reported.